Welcome to our dedicated page for Defiance Next Gen Altered Experience ETF news (Ticker: PSY), a resource for investors and traders seeking the latest updates and insights on Defiance Next Gen Altered Experience ETF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Defiance Next Gen Altered Experience ETF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Defiance Next Gen Altered Experience ETF's position in the market.
The Board of Trustees of ETF Series Solutions has decided to liquidate the Defiance Next Gen Altered Experience ETF and the Defiance Next Gen SPAC Derived ETF effective
Seelos Therapeutics, Inc. (Nasdaq: SEEL) has been added to the Defiance Next Gen Altered Experience ETF (PSY), the first U.S. ETF focused on psychedelics, which began trading on May 28, 2021. This inclusion is influenced by Seelos' lead program, SLS-002 (intranasal racemic ketamine), which has shown positive top-line data from its Proof-of-Concept study for Acute Suicidal Ideation and Behavior in patients with Major Depressive Disorder. The ETF tracks companies involved in medical psychedelics, with a minimum market cap of $75 million.
